About Us

About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Thermo Fisher Scientific Announces Latest Round of Oncomine Clinical Research Grant Awardees

By: via Business Wire

Recipients’ research focused on melanoma diagnosis, treatment response in advanced NSCLC, and bypassing common hurdles in NSCLC diagnosis and treatment

Today, Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant, recognizing research from the Melanoma Institute Australia, the University of Turin in Italy and Atrium Health Wake Forest Baptist Medical Center. The grant program, now in its seventh round of awardees, supports investigator-initiated studies with the aim to increase high-quality molecular profiling in oncology and to help democratize precision medicine.

Since its introduction in 2020, the Oncomine Clinical Research Grant program has provided up to $200,000 in reagents and general funding for 22 unique research projects conducted by independent clinical research teams. Grants have been awarded across 14 countries and five continents, spanning research topics from molecular profiling in solid-tumors, pediatric oncology, hemato-oncology, immune-oncology and liquid biopsy, all of which help to study potential new and expanded applications for accessible and rapid next-generation sequencing (NGS).

“The Oncomine Clinical Research Grant program provides us the opportunity to support emerging research projects and their goal of delivering on the promise of precision oncology through the democratization of NGS technology,” said Jose Luis Costa, Ph.D., global director, scientific affairs, clinical next-generation sequencing and oncology, Thermo Fisher Scientific. “We are committed to understanding the profound impacts NGS technology can have on clinical outcomes and are working with partners worldwide to accelerate research across this important field.”

Meet the Latest Grant Recipients

Based on the last call for proposals in Spring 2023, the following researchers and projects have been selected as the most recent grant recipients:

  • Richard Scolyer, Melanoma Institute Australia, The University of Sydney, Royal Prince Alfred Hospital, Australia – “Getting melanoma diagnosis right: migration of clinical validation of the MIA genomic ancillary test on the Genexus platform for regular clinical testing.”
    • Researchers will use the Ion Torrent Genexus system to migrate the Melanoma Institute Australia’s genomic classifier into routine clinical testing.
  • Silvia Novello and Marco Volante, University of Turin, Italy – “Integrated molecular analysis to depict signatures associated with TKI treatment response in advanced NSCLC and to identify novel predictive biomarkers.”
    • Researchers will work to fill an unmet need in precision oncology and will identify novel clinically relevant biomarkers of response to TKI in specific oncogene-addicted scenarios and increase the amount of available predictive tools of therapeutic responsiveness at baseline.
  • Wencheng Li, Atrium Health Wake Forest Baptist Medical Center, United States of America – “Biomarker Assessment by Next Generation Sequencing Using the Supernatants from Fine Needle Aspiration of NSCLC.”
    • Researchers will work to identify solutions for frequently encountered problems (inadequate specimen, indeterminate diagnosis, less-than-optimal turnaround time and false negative result) in NSCLC diagnosis and treatment.

Oncomine Clinical Research Grant Impact

In late 2023, Oncomine Clinical Research Grant recipients had the opportunity to attend a closed Oncomine Scientific Gala to share their research with the wider pharmaceutical community and showcase the results of their studies and the impact NGS testing can have on oncology research and patient care.

Dr. Elena Guerini Rocco, MD, of the European Institute of Oncology IRCCS in Italy, was a 2021 recipient of the grant program. In July of 2023, Dr. Rocco and her team published a study in The European Journal of Cancer based on their research of the immune-related aspects of pregnancy-associated breast cancer, which outlined the similarities in immune suppressive mechanisms found between normal pregnancy and breast cancer.

In relation to her team’s research, Dr. Rocco noted, “Pregnancy-associated breast cancer (PABC) is a rare and complex condition that impacts about 1 in 3,000 women. Our study supported by the Oncomine Clinical Research Grant allows us to understand the similarities of immune-related aspects of normal pregnancy and those who suffer from PABC. This brings us one step closer to identifying targeted therapies that could help patients with PABC.”

Applications for the Spring 2024 round of the Oncomine Clinical Research Grant will open March 1, 2024, and close April 30, 2024. Successful proposals should address the molecular landscape of tumors, with a focus on how molecular testing can enhance treatment precision and unlock novel strategies for improving patient outcomes. Proposals should include an outline of planned activities to be performed within a maximum of 12 months, as well as an outline of the proposed use of the requested funds.

For more information, please visit www.oncomine.com/grants.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

More News

View More
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
Via MarketBeat
Tickers JNJ KVUE PTGX
Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
Via MarketBeat
Topics Artificial Intelligence
Tickers TSLA
Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?
Via MarketBeat
Topics Bonds Stocks World Trade
Tickers ABNB DAL DOW HD
Happy Third Birthday to the Bull Market
Via MarketBeat
Topics Artificial Intelligence Stocks
Tickers NVDA PLTR TSLA
MarketBeat Week in Review – 10/13 - 10/17
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Tickers ACHR AMZN APLD APP ASTS CRM

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.